2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines

CARDIOVASCULAR THERAPY AND PREVENTION, Journal Year: 2022, Volume and Issue: 21(4), P. 3235 - 3235

Published: April 20, 2022

.

---

Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy

Russian Journal of Cardiology, Journal Year: 2021, Volume and Issue: 26(9), P. 4703 - 4703

Published: Oct. 19, 2021

.

---

Risk factors and prevention of cardiovascular complications in breast cancer

CARDIOVASCULAR THERAPY AND PREVENTION, Journal Year: 2025, Volume and Issue: 23(12), P. 4194 - 4194

Published: Feb. 13, 2025

Breast cancer (BC) is the most common malignant tumor in women. In patients who have undergone antitumor treatment at an early stage of BC, death long term more often occurs from cardiovascular diseases (CVD) than cancer. Numerous studies indicate that risk cardiomyopathy and/or heart failure, coronary artery disease among BC survivors received anthracyclines trastuzumab increased. Currently, detection cardiotoxicity using cardiac imaging and circulating biomarkers widely evaluated clinical trials. At same time, high CVDs observed cured breast a consequence both adverse effects anticancer therapy on system, including antiestrogens, presence CVD factors. Large trials reported higher rates hypertension, hypercholesterolemia, ischemic postmenopausal receiving aromatase inhibitors. Strategies for prevention left ventricular dysfunction or failure such should include comprehensive evaluation individual assessment.

Language: Английский

---

Cardioprotective Strategies for Doxorubicin-induced Cardiotoxicity: Present and Future

Rational Pharmacotherapy in Cardiology, Journal Year: 2022, Volume and Issue: 18(1), P. 103 - 112

Published: March 3, 2022

The improvement of drugs and protocols chemotherapeutic treatment has led to improved outcomes survival in patients with cancer. But along this, at first glance a positive point, there was another interdisciplinary problem, which is the need for early detection developing cardiotoxicity when taking chemotherapy drugs. study cardioprotective strategies recently become increasingly relevant, due fact that many who have successfully undergone cancer high risk or are death from cardiovascular diseases. One main number oncological diseases an anthracycline – type antibiotic-doxorubicin. This review briefly examines factors pathophysiological mechanisms underlying cardiotoxicity. current possibilities cardioprotection considered detail, some promising targets improving discussed.

Language: Английский

---

Reducing the Сardiotoxicity of Daunorubicin by Conjugation with Natural Sesquiterpene Lactones

Journal Biomed, Journal Year: 2024, Volume and Issue: 20(3), P. 37 - 46

Published: Nov. 11, 2024

We present the results of a histological study into cardiotoxicity conjugates daunorubicin with dehydrocostus lactone and epoxyisoalantolactone in mature male mice C57BL/6 line. The effect on morphology cardiomyocytes structure left ventricular myocardium was studied.

Language: Английский

---

Atrial Fibrillation Associated with Anticancer Drugs

Safety and Risk of Pharmacotherapy, Journal Year: 2020, Volume and Issue: 8(4), P. 178 - 190

Published: Dec. 17, 2020

Atrial fibrillation is a serious adverse reaction associated with the use of anticancer drugs. The aim study was to analyse scientific literature on prevalence, pathophysiological mechanisms, and risk factors drug-induced atrial fibrillation, ways its prevention treatment. results showed that incidence varies depending specific drug ranges from 1 86%. It herbal agents, alkylating protein kinase inhibitors, monoclonal antibodies, immunosuppressants, antitumor antibiotics, antimetabolites, hormonal hormone antagonists, etc. Most often, develops following such drugs as gemcitabine (in combination vinorelbine), cisplatin, melphalan, ibrutinib, cetuximab, trastuzumab, alemtuzumab, doxorubicin. demonstrated mechanisms underlying development induced by include electrophysiological abnormalities, myocardial injury, inflammation, immune response, apoptosis, oxidative stress. Risk for are not clearly defined yet continue be subject research. Prevention in cancer patients requires multidisciplinary approach involving participation an oncohematologist cardiologist. doctors charge should also vigilant regarding potential this reaction.

Language: Английский

---

Interaction of <i>CYP3A4, CYP3A5, CYP1A1 and CYP2B6</i> genes in the development of organotoxic effects of chemotherapy in patients with Hodgkin's lymphoma

Pharmacogenetics and Pharmacogenomics, Journal Year: 2024, Volume and Issue: 1, P. 31 - 43

Published: June 18, 2024

Relevance . Modern chemotherapy for Hodgkin lymphoma (HL) achieves long-term remissions in 80–85 % of patients. Some patients develop drugrelated toxicity. Polymorphisms drug-metabolizing cytochrome P450 (CYP) genes contribute to individual differences the therapeutic and side effects chemotherapy. In this regard, HL Russia has not been sufficiently studied. Objective. To study relationship between polymorphic variants CYP3A4, CYP3A5, CYP1A1 , CYP2B6 development organotoxic therapy. Methods. Polymorphic CYP3A4 (rs4987161, rs28371759, rs2740574), CYP3A5 rs776746, (rs1048943, rs4646421), (rs2279343) were determined by polymerase chain reaction with real-time detection. Their association complications was assessed odds ratio using Multifactorial Dimensionality Reduction (MDR). Results. MDR analysis showed significance four hepatotoxicity main contribution rs464642. Synergism observed rs4646421 rs227934 rs776746 antagonism The contributor cardiotoxicity which synergy both variants. anemia made synergism rs104894 noted; leukopenia — rs464642 ; granulocytopenia thrombocytopenia rs2740574 observed. Conclusion. results show that different combinations CYP are associated types organotoxicity make a major contribution.

Language: Английский

---

Age characteristics of risk cardiovascular complications in women with left breast cancer with preserved ejection fraction at the stage of chemotherapy and radiotherapy

Kardiologiia, Journal Year: 2019, Volume and Issue: 59(7S), P. 23 - 30

Published: Aug. 23, 2019

Aim. A study of the risk factors for middle-aged and elderly women HER2neu with negative left breast cancer a normal ejection fraction at stage chemoradiotherapy in everyday clinical practice. Matherial methods. 61 without severe cardiovascular pathology were examined doxorubicin therapy 3D conformal radiation therapy. Group 1 comprised 32 patients middle age (49.8 ± 4.5 years). 2 29 (68.3 3.6 In addition to Score assessment, additional factors, including psychosocial studied. All underwent ECG, echocardiography 24-hour ECG monitoring. Anxiety levels assessed using HADS scale CH. D. Spielberger –Yu.L. Khanin. The was conducted before start treatment, after completion course radiotherapy. Results discussion. patients, moderate found 21.9%, 58.6% (p = 0.0043, RR 2.68, 95% CI 1.301–5.520). high 15.6% 41.4% 0.0438, 2.648, 1061–6.607). most common studied heredity, overweight, hypercholesterolemia diabetes mellitus. had reactive anxiety. Patients have personal anxiety, After treatment cumulative dose not exceeding 360 mg/m2 , reduction below 50% 6 17.2% patients. Asymptomatic diastolic dysfunction detected 31.3% 55.2% elderly. both groups, arranging arrhythmia detected. Conclusions. obtained data indicate need in-depth examination especially an assessment conducting Echocardiography, monitoring psychological testing prevent early detection complications.

Language: Английский

---

CARDIOVASCULAR COMPLICATIONS OF ANTICANCER THERAPY: CLINICAL FEATURES, DIAGNOSIS, TREATMENT, PREVENTION (PART II)

Russian Journal of Oncology, Journal Year: 2018, Volume and Issue: 23(1), P. 43 - 49

Published: Feb. 15, 2018

The given review is devoted to the problem of cardiotoxicity chemotherapeutic agents. Many agents can cause cardiovascular complications such as left ventricular dysfunction and heart failure development, myocardial ischemia, arterial hypertension, thromboembolism, QT prolongation arrhythmias. toxic influence most often used on (such antimetabolites, alkylating agents, platinum compounds, taxanes, vinca alkaloids, monoclonal antibodies, anthracycline antibiotics, topoisomerase protein kinase inhibitors, immunomodulatory cytokines) has been described. results recent studies etiology, pathogenesis clinical features chemotherapy-induced were present in first part review. features, diagnosis, treatment prevention are described second

Language: Английский

---

CARDIOVASCULAR COMPLICATIONS OF ANTICANCER THERAPY: DEFINITION, ETIOLOGY, EPIDEMIOLOGY, PATHOGENESIS, CLASSIFICATION (PART I)

Russian Journal of Oncology, Journal Year: 2017, Volume and Issue: 22(6), P. 345 - 350

Published: Dec. 15, 2017

The given review is devoted to the problem of cardiotoxicity chemotherapeutic agents. Modern cytostatics cause clinically significant manifestations - myocardial injuries, reducing both quality and life expectancy oncological patients. Many agents can cardiovascular complications such as development left ventricular dysfunction heart failure, ischemia, arterial hypertension, thromboembolism, QT prolongation arrhythmias. toxic influence most often used on (antimetabolites, alkylating agents, platinum compounds, taxanes, vinca alkaloids, monoclonal antibodies, anthracycline antibiotics, topoisomerase protein kinase inhibitors, immunomodulatory cytokines) has been described. results recent studies etiology, epidemiology, classification pathogenesis are presented in first part review. Most attention paid research chemotherapy induced cardiotoxicity. Given numerous aspects not completely studied yet, obviously further researches needed this field.

Language: Английский

---